- Home
- DAWN
as 07-30-2025 4:00pm EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
Upcoming Earnings Alert:
Get ready for potential market movements as Day One Biopharmaceuticals Inc. DAWN prepares to release earnings report on 05 Aug 2025.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 658.9M | IPO Year: | 2021 |
| Target Price: | $30.17 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.08 - $16.76 | Next Earning Date: | 08-05-2025 |
| Revenue: | $161,922,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 17.98% | Revenue Growth (next year): | 49.50% |
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dubow Adam | DAWN | GENERAL COUNSEL | May 15 '25 | Sell | $6.26 | 4,552 | $28,485.96 | 47,136 | |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | May 15 '25 | Sell | $6.26 | 13,964 | $87,385.32 | 145,737 | |
| Merendino Lauren | DAWN | Chief Commercial Officer | May 15 '25 | Sell | $6.26 | 3,927 | $24,574.77 | 35,161 | |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | May 15 '25 | Sell | $6.26 | 4,282 | $26,796.33 | 265,231 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
GOBankingRates
2 months ago
7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
GOBankingRates
2 months ago
3 International Vacations That Are Cheaper Than an iPhone
GOBankingRates
2 months ago
Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck
Yahoo Finance
2 months ago
This week in Trumponomics: Too bad TACO isn’t true
The Guardian
2 months ago
Starmer says Farage would spook the City and give us Truss 2 – he could be right
Yahoo Finance Video
2 months ago
AI ecosystem isn't just Nvidia: Unlock it further with this ETF
Benzinga
2 months ago
Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?
Compare DAWN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.